In the skin or mucous membranes in a ‘platelet-type’ pattern, with petechiae, bruising, epistaxis and gum bleeding being common. severe bleeding manifestations such as intracra- nial hemorrhage, gastrointestinal or genitourinary bleeding and severe menstrual bleeding are relatively uncommon [ 2 , 3 ]. novel thrombopoiesis-stimulating agents have been developed to increase platelet production and thereby, cor- recting thrombocytopenia in patients with itp [ 4 ]. these compounds called thrombopoietin (tpo) receptor agonists (tpo-ras) and show no structural resemblance to tpo but still bind and activate the tpo receptor (tpo-r) [ 5 ]. eltrombopag is an oral, non-peptide, tpo-ra that stimu- lates thrombopoiesis, leading to increased platelet pro-duction. eltrombopag has been reported to be an effective

HIGHLIGHTS

• who: Chronic ITP Eltrombopag GPV et al. from the Pediatrics Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt have published the research work: in the skin or mucous membranes in a u2018platelet-typeu2019 pattern, with petechiae, bruising, epistaxis and gum bleeding being common. Severe bleeding manifestations such as intracra- nial hemorrhage, gastrointestinal or genitourinary bleeding and severe menstrual bleeding are relatively uncommon [ 2 , 3 ]. Novel thrombopoiesis-stimulating agents have been developed to increase platelet production and thereby, cor- recting thrombocytopenia in patients with ITP [ 4 ]. These compounds called thrombopoietin (TPO) receptor agonists (TPO-RAs) and show . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.